Research output per year
Research output per year
Personal profile
Professional Information
I am medical oncologist trained in Chile and formally trained again at the National Cancer Institute National Institutes of Health, Bethesda MD, obtaining my second oncology fellowship. Additionally, I have received direct lung cancer training from prestigious investigators such as Guiseppe Giacconne MD and medical Oncology mentorship by Antonio Fojo.
Research Interests
My main interest are immuno-oncology specific diseases such as lung cancer, renal cancer and melanoma and areas in medicine like Health policy and biostatistics. I was editor of the Seminar in Oncology journal and currently I am one of the editors of Journal of Thoracic Oncology. I have participated in more than 50 publications in indexed journals and have written several medical oncology books chapters. I am also the Medical Director of the Cancer Center of Clínica Universidad de los Andes and the Medical Director of Bradford Hill clinical research center and have participated as principal investigator in more than 30 cancer clinical trials.
External positions
Medical Director, Bradford Hill Clinical Research Center.
1 Mar 2019 → …
Fingerprint
Dive into the research topics where Mauricio Burotto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
Renner, A., Burotto, M., Valdes, J. M., Roman, J. C. & Walton-Diaz, A., 2021, In: Therapeutic Advances in Urology. 13Research output: Contribution to journal › Review article › peer-review
Open Access -
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
CheckMate 9ER Investigators, 4 Mar 2021, In: New England Journal of Medicine. 384, 9, p. 829-841 13 p.Research output: Contribution to journal › Article › peer-review
-
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
for the PHranceSCa study group, Jul 2021, In: European Journal of Cancer. 152, p. 223-232 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We Thought
Salinas, C., Samtani, S. & Burotto, M., Jan 2021, In: Oncologist. 26, 1, p. e191Research output: Contribution to journal › Letter › peer-review
Open Access -
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Felip, E., Burotto, M., Zvirbule, Z., Herraez-Baranda, L. A., Chanu, P., Kshirsagar, S., Maiya, V., Chan, P., Pozzi, E., Marchand, M., Monchalin, M., Tanaka, K., Tosti, N., Wang, B. & Restuccia, E., 2021, (Accepted/In press) In: Clinical Pharmacology in Drug Development.Research output: Contribution to journal › Article › peer-review
Open Access
Press / Media
-
Does cytoreductive nephrectomy remain an essential component of care for advanced renal cell carcinoma?
25/06/19
1 item of Media coverage
Press/Media
-
New technique facilitates tumor detection and avoids intervention
4/06/18
1 item of Media coverage
Press/Media
-
Recurrent Respiratory Papillomatosis and Bevacizumab Treatment
2/10/17
1 item of Media coverage
Press/Media
-